Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Reaman

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|November 3, 2022
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?Andrew D J Pearson, Teresa de Rojas, Dominik Karres, et al.
Journal of the National Cancer Institute|November 17, 2023
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug developmentAndrew D J Pearson, Teresa de Rojas, Dominik Karres, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupHolly J Meany, Nita L Seibel, Mark Krailo, et al.
Leukemia & Lymphoma|December 16, 2006
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144PPaul C Nathan, Trish Whitcomb, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study GroupSmita Bhatia, Yutaka Yasui, Leslie L Robison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Recommendations for the return of research results to study participants and guardians: a report from the Children's Oncology GroupConrad V Fernandez, Kathleen Ruccione, Robert J Wells, et al.
JCO Clinical Cancer Informatics|December 10, 2025
Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative ToolsSubhashini Jagu, Jaime M Guidry Auvil, Mark Cunningham, et al.
Journal of Clinical Pharmacology|January 23, 2020
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and VomitingJeremiah D Momper, M Tobias Heinrichs, Kevin Krudys, et al.
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|November 3, 2022
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?Andrew D J Pearson, Teresa de Rojas, Dominik Karres, et al.
Journal of the National Cancer Institute|November 17, 2023
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug developmentAndrew D J Pearson, Teresa de Rojas, Dominik Karres, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupHolly J Meany, Nita L Seibel, Mark Krailo, et al.
Leukemia & Lymphoma|December 16, 2006
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144PPaul C Nathan, Trish Whitcomb, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study GroupSmita Bhatia, Yutaka Yasui, Leslie L Robison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Recommendations for the return of research results to study participants and guardians: a report from the Children's Oncology GroupConrad V Fernandez, Kathleen Ruccione, Robert J Wells, et al.
JCO Clinical Cancer Informatics|December 10, 2025
Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative ToolsSubhashini Jagu, Jaime M Guidry Auvil, Mark Cunningham, et al.
Journal of Clinical Pharmacology|January 23, 2020
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and VomitingJeremiah D Momper, M Tobias Heinrichs, Kevin Krudys, et al.
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
Pageof 9